Speciality
Spotlight

 




           

Clinical Pharmacology

       

     





Malaria

   

  • Lell
    Bertrand, Faucher Jean-Francois, et al.

    Malaria chemoprophylaxis with tafenoquine: a randomised study.

     


    Background:
    Tafenoquine is an analogue of primaquine with an improved
    therapeutic and safety profile. It
    has a long half-life and activity against liver-stage malaria
    parasites, so may be useful for chemoprophylaxis.

     

    It
    has the potential to replace currently used drugs for malaria
    chemoprophylaxis.

        

  • Peerapan Tanariya, Pongsri Tippawangkoso, Juntra Karbwang, Kesara Na-Bangchang & Walther H Wernsdorfer. (Dept of Microbiology, Mahidol Univ, Bangkok, Unit of Clinical Pharmacology, Faculty of Tropical Medicine, Institute of Specific Prophylaxis, Univ of Vienna, Austria).

    In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol ) and artemether.

    Br J Clin Pharmacol, 49, 437-444.

        


    The common finding that Plasmodium falciparum is often resistant to drugs may not be due to development of resistance to antimalarial drugs. There is a possibility that in the lower dose regimen, either the dose may be inadequate or administration is of too short a duration. It is possible that by increasing the dose and the duration of treatment, many of the so-called treatment failures could be overcome.

        

  • F
    Nosten, M van Vugt, et al (Department of Infectious
    Diseases, Tropical Medicine and AIDS, Amsterdam,
    Netherlands)

    In
    this area of Thailand, early diagnosis and treatment
    with combined artesunate and mefloquine has reduced
    the incidence of plasmodium falciparum malaria and
    halted progression of mefloquine resistance.
    Authors recommend that antimalarial drugs
    should be combined with artemisinin or a derivative
    to protect them against resistance.

        



  
 



 

     

Speciality Spotlight

 

           
Clinical Pharmacology
       

     

Malaria
   

  • Lell Bertrand, Faucher Jean-Francois, et al.
    Malaria chemoprophylaxis with tafenoquine: a randomised study.
     
    Background: Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis.
     
    It has the potential to replace currently used drugs for malaria chemoprophylaxis.
        

  • Peerapan Tanariya, Pongsri Tippawangkoso, Juntra Karbwang, Kesara Na-Bangchang & Walther H Wernsdorfer. (Dept of Microbiology, Mahidol Univ, Bangkok, Unit of Clinical Pharmacology, Faculty of Tropical Medicine, Institute of Specific Prophylaxis, Univ of Vienna, Austria).
    In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol ) and artemether.
    Br J Clin Pharmacol, 49, 437-444.
        
    The common finding that Plasmodium falciparum is often resistant to drugs may not be due to development of resistance to antimalarial drugs. There is a possibility that in the lower dose regimen, either the dose may be inadequate or administration is of too short a duration. It is possible that by increasing the dose and the duration of treatment, many of the so-called treatment failures could be overcome.
        

  • F Nosten, M van Vugt, et al (Department of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands)
    In this area of Thailand, early diagnosis and treatment with combined artesunate and mefloquine has reduced the incidence of plasmodium falciparum malaria and halted progression of mefloquine resistance. Authors recommend that antimalarial drugs should be combined with artemisinin or a derivative to protect them against resistance.
        

    

 

By |2022-07-20T16:43:54+00:00July 20, 2022|Uncategorized|Comments Off on Malaria

About the Author: